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The principal Epstein–Barr virus (EBV) oncoprotein, latent membrane protein 1 (LMP1) is strongly associated with
nasopharyngeal carcinoma (NPC), a prevalent cancer in China. The epidermal growth factor receptor (EGFR) is
important in carcinogenesis, as it is a ubiquitously expressed receptor tyrosine kinase. Signal transducer and
activator of transcription 3 (STAT3) is a master transcriptional regulator in proliferation and apoptosis. Our previous
study demonstrated that the nuclear EGFR could bind to the cyclin D1 promoter directly in the presence of LMP1,
and the correlation between EGFR and STAT3 in NPC remains to be further explored. Here, we have shown that the
interaction of EGFR and STAT3 increased in the nucleus in the presence of LMP1. LMP1 promoted both EGFR and
STAT3 binding to the promoter region of cyclin D1, in turn, enhancing the promoter activity of cyclin D1.
Furthermore, we demonstrated that both transcriptional activity and mRNA levels of cyclin D1 were decreased by
small molecule interference of EGFR and STAT3 activity. These findings may provide a novel linkage between the
EGFR and STAT3 signaling pathways and the activation of cyclin D1 by LMP1 in the carcinogenesis of NPC.
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Epstein-Barr virus (EBV) is a ubiquitous herpes virus that
is linked to multiple malignancies, including Burkitt’s
lymphoma, Hodgkin’s disease, gastric cancer esophageal
cancer cervical cancer and prostate cancer and nasopha-
ryngeal carcinoma (NPC) [1-9]. Latent membrane protein
1 (LMP1) encoded by EBV functions as an essential factor
in EBV-induced cell transformation and is expressed in
many of the malignancies associated with EBV. LMP1
protein is detected in approximately 60 percent of tissue
samples from patients with NPC [10,11], while LMP1
mRNA is detected in nasopharyngeal swabs in over 90%
of NPC patients by RT-PCR [12,13]. The frequent expres-
sion of LMP1 in undifferentiated NPC points to a role for* Correspondence: taoyong@csu.edu.cn; ycao98@vip.sina.com
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reproduction in any medium, provided the orthis viral oncoprotein as a key molecule in NPC patho-
genesis [14-19].
Elevated amounts of the epidermal growth factor re-
ceptor (EGFR) at both the protein and mRNA levels are
detected in the epithelial cell carcinomas including NPC,
and its expression correlates with the levels of LMP1
[20]. Our earlier research reports that LMP1 may in-
crease both expression and phosphorylation levels of
EGFR [21,22] and that LMP1 could regulate the nuclear
accumulation of EGFR in a dose-dependent manner
quantitatively and qualitatively [23]. We also showed
that nuclear EGFR could bind to the cyclin D1 promoter
directly and transactivate the cyclin D1 promoter by
LMP1 in NPC. Many factors such as the epidermal
growth factor, the DNA damage factor, ultraviolet irra-
diation, radiation and cetuximab increase EGFR trans-
location into the nucleus [24-29]. These findings clearly
indicate that EGFR may act as a new factor that directly
target genes related to cellular transformation, cell cycle
regulation, DNA damage repair and replication.This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(STAT3) is a member of the STAT family of cytoplasmic
proteins that is constitutively active in many human can-
cers [30,31]. Upon stimulation by cytokines or growth
factors, STAT3 translocates into the nucleus to upre-
gulate numerous target genes, such as cyclin D1, c-fos,
c-Myc, Bcl-XL, and VEGF, stimulating cell proliferation
and preventing apoptosis. Overexpression and activation
of STAT3 is strongly associated with NPC [32-34]. Our
previous finding showed that EBV LMP1 stimulates the
phosphorylation of STAT3 at both tyrosine 705 (Tyr
705) and serine 727 (Ser 727) [35]. Furthermore, we
demonstrated that LMP1 signals through the Janus kin-
ase 3 (JAK3) and extracellular signal-regulated kinase
1/2 (ERK1/2) pathways upon the activation (or transac-
tivation) of STAT3. LMP1 may induce vascular endothe-
lial growth factor (VEGF) expression via the JAK/STAT
and mitogen-activated protein kinase (MAPK)/ERK sig-
naling pathways [34]. The relationship between LMP1
regulated STAT3 and other target genes remain unclear.
Cyclin D1 is a key regulatory protein at the G1/S
checkpoint of the cell cycle. A recent census concluded
that cyclin D1 gene amplification and overexpression
are present in breast cancer, lung cancer, melanoma and
oral squamous cell carcinomas [30,36,37]. Our previous
studies have shown that LMP1 can activate cyclin D1
gene expression [38], upregulate the promoter activity
of cyclin D1 by inducing c-Jun/Jun B heterodimers [39]
and via EGFR transcriptional activity as well as tran-
scriptional intermediary factor 2 (TIF2) interaction [40]
in NPC cell lines. Therefore, we explored whether
LMP1 regulated transactivation of the cyclin D1 pro-
moter via activated EGFR and STAT3 in NPC would
provide a new link in understanding the mechanisms of
carcinogenesis and progression of NPC.
In this study, we found that LMP1 promoted the inter-
action of EGFR and STAT3 in the nucleus. The nuclear
EGFR and STAT3 could target the cyclin D1 promoter
directly, in turn, upregulating the cyclin D1 promoter
activity and mRNA level. Furthermore, knockdown of
EGFR and STAT3 decreased cyclin D1 promoter activity.
Our results provide a novel linkage between deregulated
EGFR signaling and the activation of cyclin D1 gene
expression induced by LMP1 in NPC tumorigenesis.
Material and methods
Cell lines
CNE1 is an LMP1-negtive, poorly differentiated NPC
cell line. CNE1- LMP1 is a stably transfected cell
line, established by introducing LMP1 cDNA into
CNE1 cells, and the cell line stably expressing LMP1
[17,34,41-43]. Two cell lines were grown in RPMI
1640 (GIBCO BRL, U.S.A.), containing 10% fetal calf
serum and 100 U/ml penicillin/streptomycin, and allcell lines grew, at 37°C under 5% CO2 and 95% air at
99% humidity.
Plasmids
Plasmid (pCCD1-Luc), kindly provided by Dr. Strauss M,
contained 3.9 kb of the human cyclin D1 promoter cloned
into the multiple cloning sites of pBSK+, driving the gene
expression for firefly luciferase. The pcDNA3.1-EGFR ex-
pression plasmid was constructed by cloning the whole
EGFR coding fragment into XhoI sites of the pcDNA3.1
vector. Expression plasmid for dominant negative mutant
of EGFR (EGFR-DN) had a deletion of 533 amino acids at
the N terminus, which competitively inhibited the activa-
tion of EGFR, and was cloned into pcDNA3.1. The pSG5-
STAT3 was obtained from whole STAT3 coding fragment
cloned into XhoI sites of the pSG5 vector. Expression
plasmid for dominant negative mutant of STAT3
(STAT3β) had a deletion of 55-residue in C-terminal
transactivation domain of STAT3 and replaced by seven
unique C-terminal residues (CT7) [44]. The EGFR and
STAT3 motif mutation (designated as pD1-mut-Luc)
from pCCD1-Luc were generated by PCR based on an
overlap extension technique. The primers used for
generating mutations were: 5′- CTCCACCTCACCCCC-
TAAAT-3′ and 5′-AGGGATGGCTTTTGGGCTCT -3′.
PCR-amplified fragments carrying the desired mutations
were then cloned into Xba I sites of the pBSK + vector.
The construction of expected TAKARA Biotechnology
completed mutations and the sequencing of integrity
of the vector. DNAzyme 1 (DZ1) is an LMP1-targeted
DNAzyme that binds and cleaves LMP1 RNA in a highly
sequence-specific manner [19]. And the control oligo-
nucleotide of DZ1 (TAKARA, China) was designed by
inverting the catalytic core sequence. To monitor transfec-
tion efficiency, pRL-SV40 (Promega, U.S.A) was used as
an internal control.
Preparation of cell lysates and cell fractions
For whole cell lysates, 107/ml cultured cells were har-
vested and washed twice with ice-cold phosphate-buffered
saline (PBS), and then lysed in the 500 μl lysis buffer
[10 mM Tris–HCl, pH 8.0; 1 mM EDTA, 2% sodium do-
decyl sulfate (SDS); 5 mM dithiothreitol (DTT); 10 mM
phenylmethyl sulfonylfluoride (PMSF); 1 mM Na3VO4;
1 mM NaF; 10% (vol/vol) glycerol; protease inhibitors
cocktail tablet (Roche, Switzerland)] for 30 min on ice and
centrifuged at 15,000 × g for 10 min. The supernatant was
collected and stored at −70°C until used.
For Preparation of cytoplasmic and nuclear fractions,
107/ml cells were washed with PBS and suspended in
200 μl of lysis buffer (10 mM Hepes, pH 7.9; 10 mM
KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM DTT;
0.5 mM PMSF; and protease inhibitor cocktail). The
cells were incubated on ice for 15 min, after which 6.5 μl
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then centrifuged for 1 min at 12,000 rpm. The super-
natant was saved as cytoplasmic fraction. The pellet was
resuspended in 12.5 μl of ice-cold nuclear extraction
buffer (20 mM Hepes, pH 7.9; 0.4 M NaCl; 1 mM
EDTA; 1 mM EGTA; 1 mM DTT; 1 mM PMSF; and
protease inhibitor cocktail) and incubated on ice for
40 min with mixing every 10 min, then they were centri-
fuged for 5 min at 12,000 rpm at 4°C. The supernatant
was saved as nuclear fraction. The cytosolic and nuclear
fractions were stored at −70°C until used.
Western blot analysis
Fifty microgram (μg) of the total proteins from cell pre-
parations were separated on 10% SDS- polyacrylamide
gel electrophoresis and then electrotransfered onto the
nitrocellulose membrane. The membranes were blocked
with buffer containing 5% non-fat milk in PBS with
0.05% Tween-20 (PBST) for 2 hrs, and incubated with
different primary antibodies (anti-EGFR or anti-STAT3)
overnight at 4°C. After second wash with PBST, the
membranes were incubated with anti-rabbit (sc-2004,
Santa Cruz, U.S.A.) or anti-mouse (sc-2005, Santa Cruz,
U.S.A.) horseradish peroxidase- conjugated secondary
antibody for 1 hr. at room temperature and color was
developed with the enhanced chemiluminescence de-
tection kit (ECL, Pierce, U.S.A.), then, and followed by
exposure to autoradiographic film. The antibodies used
were as follows: EGFR (sc-03-G, Santa Cruz, U.S.A.),
p-EGFR (sc-12351, Santa Cruz, U.S.A.), STAT3 (#9132,
Cell Signaling Technology, U.S.A.), p-STAT3 (#9131,
Cell Signaling Technology, U.S.A.), β-actin (sc-8432,
Santa Cruz, U.S.A.), α-tubulin (sc-5286, Santa Cruz,
U.S.A.), Nucleolin (sc-8031, Santa Cruz, U.S.A.), cyclin
D1 (Cat# 2261–1, Epitomics, U.S.A.).
Co-immunoprecipitation analysis and immunoblotting
analysis
Cell extracts were prepared with harvested cells from
CNE1 and CNE1-LMP1 lysed in an immunoprecipi-
tation (IP) lysis buffer (50 mM Tris–HCl, 150 mM NaCl,
10% NP-40, 1 mM EDTA, 10% glycerol, 10 mM NaF,
1 mM Na3VO4, 1 mM DTT, 1 mM PMSF, and protease
inhibitor cocktail tablet). Two milligram (mg) of protein
prepared were mixed with 40 μl of protein A-Sepharose
beads (Sigma, U.S.A.) in the IP assay buffer (1× PBS,
0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS), incubated at 4°C for 2 hrs with gentle agitation
and centrifuged for 10 min at 2,000 rpm for preclearing.
The recovered supernatant was incubated with either
2 μg of anti-EGFR or 2 μg of anti-STAT3in the pre-
sence of 1× protease inhibitors at 4°C overnight with
mild shaking. Followed by addition of 50 μl of Protein
A-Sepharose beads and the incubation were continuedfor 2 hrs at 4°C with gentle shaking. Then, Protein
A-precipitated protein complex was recovered by cen-
trifugation for 10 sec. at 12,000 rpm and followed
washed three times with IP assay buffer, the harvested
beads were resuspended in 30 μl of 2× SDS PAGE sam-
ple buffer were boiled for 5 min. to release the bound
protein. A 20 μg aliquot of cell lysate was used as an
input control. The samples were then analyzed by
Western blot. Antibodies for Western blot detection
were EGFR IgG antibody and STAT3 IgG antibody.
Transient transfection and luciferase assay
Cells were cultured in 24-well plates at a density of 1 × 105
per well overnight and were transfected with Lipofecta-
mine™ 2,000 (Invitrogen, U.S.A.) as the manufacturer’s
instructions. Each transfection contained 800 ng/well of
pCCD1-Luc or pD1-mut-Luc firefly luciferase reporter
and 80 ng/well of internal control pRL-SV40 or contained
400 ng/well of firefly luciferase reporter and 80 ng/well of
internal control pRL-SV40 together with 200 ng/well of
each expression plasmid or blank expression plasmid
necessary to normalize the amount of DNA transfected.
Twenty-four hrs. after transfection, cells were harvested
at 36 hrs. after transfection and lysates were analyzed
for luciferase activity using the Dual Luciferase Reporter
assay (Promega, U.S.A.) according to the manufacturer’s
directions with a GloMax™ Microplate Luminometer
(Promega, U.S.A.). The luciferase reporter plasmids were
co-transfected with pRL-SV40 to correct for variations
in transfection efficiency. The relative luciferase activity
normalized to the value of pRL-SV40 activity. Results were
expressed as fold induction of pCCD1-Luc activity in
CNE1 cells, which was assigned a value of 1. WHI-P131,
PD98059 and AG1478 inhibited the activities of cyclin
D1 induced by stable expression LMP1. CNE1-LMP1
cells were transfected with cyclin D1 promoter-reporter
construct and Renilla luciferase plasmid as an internal
control. The data represent the mean ± SD of the three
independent experiments performed in triplicate.
To observe WHI-P131, PD98059 and AG1478 inhi-
biting the activities of cyclin D1 induced by stable ex-
pression LMP1, 24 hrs. after transfection, cells were
treated with WHI-P131 (Calbiochem, U.S.A. ), PD98059
(Cell Signalling Technology, U.S.A. ), AG1478 (Cell Sig-
nalling Technolgoy, U.S.A.) or 0.1% DMSO for 2 hr.
Cells were harvested at 26 h after transfection and sub-
jected to the luciferase assay. Empty firefly reporter vec-
tor served as the negative control.
Electrophoretic mobility shift assay (EMSA)
EMSA for EGFR/STAT3 binding to cyclin D1 was
performed using the LightShift™ Chemiluminesent EMSA
kit (Pierce, U.S.A ) and was conducted according to
the manufacturer’s protocol. Briefly, Double-stranded
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labeling (Invitrogen, U.S.A ). Ten μg of nuclear extracts
were incubated with 2 μl biotin-labeled probes in binding
buffer for 20 min. at room temperature. Additionally,
increasing concentrations of 200- fold of excess of a
cold competitive oligonucleotide (biotin- unlabeled probe)
and NF-κB biotin-unlabeled probe (as a nonspecific com-
petitive probe) were added to confirm specificity of the
interaction. The reaction mixture was then loaded onto
10% non- denaturing polyacrylamide gel containing 0.5×
Tris borate (TBE) and electro- phoresed in 0.5× TBE at
4°C prior to visualization according to the manufacturer;
Followed by transferred to BiodyneR B Nylon membrane,
avidin-HRP to probes, and visualized and quantitated
with a PhosphorImager (Bio Rad, U.S.A). All the double-
stranded probes were synthesized as follows: for the
putative binding site of EGFR in the cyclin D1 promoter:
5′-TCGCTGAGATTCTTTGGCCGTCTG-3′ (wild type)
and 5′-TCGCTGAGATACTCGGGCCGTCTG-3′ (mu-
tated type). For the STAT3 binding site in cyclin D1
promoter: 5′-GTGGCGTTCTTGGAAATGCG- CCCA-
3′ (wild type) and 5′-GTGGCGAGCTTGTGAATGCG
CCCA-3′ (mutated type).
To verify the involvement of EGFR, STAT3, LMP1 in
the complex, DZ1, small molecular inhibitors AG1478,
WHI-P 131and PD98059, was added to the mixture con-
taining the nuclear extracts and biotin-labeled probes
and incubated at room temperature or on ice for an
additional 10 min.
RNA interference
We used EGFR siRNA and STAT3 siRNA to reduce
EGFR and STAT3 gene expression. The siRNA se-
quences for EGFR (sc-29301, Santa Cruz, U.S.A) and
STAT3 (sc-29493, Santa Cruz, U.S.A ), and the negative
control siRNA (sc-37007, Santa Cruz, U.S.A ) (silencer
negative control) were purchased from Santa Cruz. Cells
were plated at 30% to 40% confluency, in RPMI 1640
and 10% FCS. The indicated siRNA (100 pmol EGFR
siRNA; and/or 100 pmol of STAT3 siRNA) was trans-
fected in six-well plates using 10 μl Lipofect AMINE as
recommended (Invitrogen, U.S.A ) for 6 hrs. in serum-
free medium. Medium containing serum was added to
bring the concentrations of serum to those indicated
above.
To study transcriptional activity of endogenous EGFR
and STAT3, cells were transiently cotransfected with
pCCD1-Luc, and 10 nM of the noncoding control
siRNA as a control.
RT-PCR and quantitative real-time PCR
Cells were transfected with the specified siRNAs and
placed in RPMI 1640 with 5% FCS. Forty-eight hours
later, they were harvested for RNA isolation using Trizol(Invitrogen, U.S.A). RNA was reverse transcribed with
random primers and SuperScript II reverse transcriptase
according to Invitrogen’s protocol. The RT Real-Time
SYBR/ROX PCR Master Mix was purchased from
TAKARA; and PCR analysis was performed on an Applied
Biosystems 7500 Real-Time PCR System, according to the
instructions of the manufacturer. The RT-PCRs were per-
formed in duplicates for four independent experiments
and the results were normalized to the respective expres-
sion levels of actin. The primer sequences were for cyclin
D1 (forward) 5′-CTCCACCTCACC- CCCTAAAT -3′
and (reverse) 5′-AGAGCCCAAAAGCCATCC-3′ and for
actin (forward) 5′-TTCC- AGCCTTCCTTCCTGGG-3′
and (reverse) 5′-TTGCGC- TCAGGAGGAGCAAT-3′.
The amplification product of cyclin D1 was 177 bp. The
mean ± SD of three independent experiments is shown.
Flow cytometry
Flow cytometry was used to quantify cells in each phase of
the cell cycle. Cells (2 × 105) were plated into 6-well plates
and treated with the indicated siRNAs after 24 hrs. Cells
were harvested after an additional 72 hrs, washed with
PBS and fixed in 70% ethanol overnight at 4°C. To detect
the fluorescent intensity of certain proteins, cells were
counterstained in the dark with 50 μg/ml phosphatidyl
inositol (PI) and 0.1% ribonuclease A (RNase A) in 400 μl
of PBS at 25°C for 30 min. Stained cells were assayed
and quantified using a FACSort Flow Cytometer (Becton
Dickinson, U.S.A).
Statistical analysis
All statistical calculations were performed with the sta-
tistical software program SPSS ver.10.0. Differences bet-
ween various groups were evaluated by the Student’s
t test. The difference was of statistical significance, when
p <0.05.
Results
LMP1 promoted the interaction of EGFR with STAT3 in
NPC cells
To investigate the possible interaction of EGFR and
STAT3 in NPC cells, co-immunoprecipitation (co-IP)
with immunoblot analysis was performed. An anti-EGFR
antibody pulled down an immunocomplex, and then
Western blotting was performed to analyze the STAT3
protein in the complex. Data in Figure 1A show that
EGFR interacted with STAT3 using an anti-EGFR anti-
body while LMP1 increased the interaction of EGFR
with STAT3. In addition, Figure 1B indicates that STAT3
interacted with EGFR using an anti-STAT3 antibody,
and the interaction of STAT3 with EGFR increased
under the regulation of LMP1. Our previous study de-
monstrated that LMP1 promoted the phosphorylation of
STAT3 and EGFR [35,45], Additional file 1: Figure S1
Figure 1 LMP1 affected the interaction of EGFR and STAT3. Two mg of protein from cell lysates were immunoprecipitated with an anti-EGFR
antibody (A) or anti-STAT3 antibody (B) and analyzed by Western blotting with a STAT3 and EGFR antibodies. Negative controls included
immunoprecipitation with an unrelated antibody (IgG). ®-actin were used as an internal control of Inuput. The bottom panels show the 50 μg
of input materials. IP: immunoprecipitation, IB: immunoblot, kDa: kilodalton.
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phosphorylated STAT3 increased in the presence of
LMP1. These data indicate that EGFR interacts with
STAT3 in NPC cells with LMP1 increasing the interaction.LMP1 induced EGFR and STAT3 nuclear translocation in
NPC cells
To confirm the interaction of EGFR with STAT3 in the
nucleus under the regulation of LMP1 at the cellular
sublocalization level, co-IP and Western blotting were
performed from both cytosolic and nuclear fractions.
Cytosolic fractions and nuclear extracts were prepared
from CNE1 and CNE1-LMP1 cells, and a co-IP was
performed with anti-EGFR (Figure 2A) or anti-STAT3
(Figure 2B) specific antibodies. Nucleolin was used as a
control for nuclear extractions while α-tubulin was
regarded as a cytosolic extraction control (input panels
of Figure 2A). Immunoprecipitation with anti-EGFR anti-
body in Figure 2A shows that EGFR interacted with
STAT3 in both the cytoplasm and nucleus, while LMP1
increased the presence of an EGFR and STAT3 immuno-
complex in the nucleus. The IgG control did not detect an
EGFR and STAT3 immunocomplex. Using an anti STAT3
antibody, Figure 2B further confirmed that STAT3 inter-
acted with EGFR and that LMP1 promoted the interaction
of EGFR with STAT3 in the nucleus. Taken together, these
data indicate that LMP1 increased the accumulation of
EGFR and STAT3 in the nucleus and shifted the inter-
action of EGFR with STAT3 from the cytosolic fraction
into the nucleus of NPC cells.LMP1 activated the activity of cyclin D1 promoter by the
EGFR and STAT3 pathways
Because cyclin D1 contains both EGFR and STAT3 binding
sites adjacent within three nucleotides[31], we addressed
whether nuclear accumulation and the interaction between
EGFR and STAT3 at the cyclin D1 promoter was under
the regulation of the oncoprotein LMP1. The effect of
LMP1 on the transcriptional activation of cyclin D1 was
examined using a luciferase reporter construct, pCCD1-
wt-Luc, driven by the cyclin D1 promoter that contained
both EGFR and STAT3 binding sites (Figure 3A). First, we
constructed a mutant cyclin D1 promoter luciferase re-
porter plasmid, pCCD1-mt-Luc, to which no transcription
factors would bind at a cyclin D1 promoter region accord-
ing to a database search (TFSEARCH, http://www.cbrc.jp/
research/db/TFSEARCH) (Figure 3A). Then, we trans-
fected the plasmid into CNE1 and CNE1-LMP1 cells, and
LMP1 increased the cyclin D1 promoter activity while the
mutant cyclin D1 promoter decreased the cyclin D1 pro-
moter activity (column 5 and column 6 of Figure 3B). As
shown in Figure 3B, EGFR increased the luciferase expres-
sion in CNE1-LMP1 cells (column 7) but not in CNE1
cells (column 3). Mutations in the cyclin D1 promoter
greatly (column 6) were attenuated its transcriptional activ-
ity in the presence of LMP1 while EGFR rescued the cyclin
D1 promoter activity partially (column 8), indicating that
LMP1 positively regulates the activity of the cyclin D1 pro-
moter under EGFR. Furthermore, data in Figure 3C dem-
onstrate that STAT3 increased the activity of the cyclin D1
promoter in the presence of LMP1 (column 7 of Figure 3C)
while the cyclin D1 promoter activity were decreased
Figure 2 LMP1 induced co-localization of EGFR and STAT3 in the nucleus. Endogenous association of EGFR (A) with STAT3 (B) in NPC cells
without or with LMP1 expression. Equal amounts of fractionated cellular proteins were immunoprecipitated with an anti-EGFR or anti-STAT3
antibody and loaded for Western blotting. Input samples from equal amounts of proteins blotted for EGFR, STAT3, nucleolin, and α-tubulin are
shown as loading and fractionation controls. N: nuclear fraction, C: cytosolic fraction, IB: immunoblot.
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in the Cyclin D1 promoter (column 8 of Figure 3C), further
indicating that LMP1 upregulates the activity of the cyclin
D1 promoter through STAT3.
Inhibitors of both EGFR and STAT3 signaling pathways
attenuated LMP1-augmented cyclin D1 promoter
activities and protein levels
Abnormal cell cycle regulation due to Cyclin D1 over-
expression is a common occurrence in human cancers
(including NPC), and both EGFR and STAT3 could tar-
get cyclin D1 promoter activity [31,35,46]. To further
confirm whether the EGFR signaling pathway affects the
activity of the cyclin D1 promoter directly, a dominant-
negative (DN) variant of EGFR lacking 533 amino acids
of the cytoplasmic domain, EGFR-DN [47], was used. The
mutant is able to block signaling stemming from several
members of the ErbB family and other receptor tyrosine
kinases (RTKs). Meanwhile, a specific DNAzyme DZ1 that
is targeted to the transmembrane domains of LMP1[19]
decreased the level of LMP1 expression. Figure 4A de-
monstrated that both DZ1 and EGFR-DN decreased the
activity of the cyclin D1 promoter in the presence of
LMP1. However, in the presence of EGFR-DN, DZ1 had
almost no inhibitory effect on the cyclin D1 promoter
activity. STAT3β lacks 55-residues in the C-terminal
transactivation domain that is present in STAT3α. Instead,
seven unique C-terminal residues act as their full-length
counterpart by virtue of missing the C-terminal trans-
activation domain [44]. Additionally, Figure 4B shows that
STAT3β attenuated cyclin D1 promoter activity. Incontrast DZ1 inhibitory effect was intact in the presence
of STAT3β. Nevertheless DZ1 and STAT3β inhibitory ef-
fects are not synergistic.
Nuclear accumulation of EGFR and STAT3 is de-
pendent on the activation of the related signaling path-
ways. CNE1-LMP1 cells were treated with the small
molecule inhibitor WHI-P131, a specific inhibitor of
STAT3 phosphorylation at residue tyrosine 705 and
serine 727. Both the promoter activity (Figure 4C) and
the protein level (Figure 4D) of cyclin D1 decreased
greatly upon WHI-P131 treatment. Treatment with
PD98059, a chemical inhibitor that blocks the nuclear
translocation of STAT3, also decreased cyclin D1 promoter
activity (Figure 4C) and protein expression (Figure 4D).
On the other hand, the data in Figure 4C and Figure 4D
indicated that AG1478, an EGFR specific tyrosine kin-
ase inhibitor, decreased the transcriptional activity of
the cyclin D1 promoter and protein level. WHI-P131
was less efficient in the presence of PD98059 in cyclin
D1 transcription (Figure 4C) but not cyclin D1 protein
level (Figure 4D). siSTAT3 or WHI-P131 induced a
stronger inhibition of cyclin D1 promoter activity than
siEGFR or AG1478. Taken together, these data suggest
that both EGFR and STAT3 signaling pathways are in-
volved in the transcriptional activity of Cyclin D1 pro-
moter and protein levels.
LMP1 regulated the nuclear EGFR and STAT3 binding to
the cyclin D1 promoter region directly
Next, we addressed whether the nuclear interaction of
EGFR and STAT3 associates with the cyclin D1
Figure 3 Identification of an EGFR and STAT3 response element in the cyclin D1 promoter. (A) Schematic diagram of mutant cyclin D1
promoter constructs are shown. The expansion for EGFR and STAT3 binding site illustrates the wild-type sequence and frames the nucleotides
replaced by mutations. (B-C) Dual luciferase-reporter assays were performed in LMP1-negative and LMP-positive CNE1 cells after co-transfection
of a wild type or mutant cyclin D1 promoter-reporter construct, plasmids expressing wild-type EGFR or STAT3, and a Renilla luciferase transfection
control plasmid. The fold induction by EGFR and STAT3 is displayed as the ratio of promoter activity obtained with wild-type compared to the
DNA-binding mutant. (mean ± SD, n = 3, *p < 0.05, **p < 0.01). mt: mutation, wt: wild-type.
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assay (EMSA) in CNE1 and CNE1-LMP1 cells. The
probes, which contain EGFR or STAT3 binding sites ac-
cording to the previous report [31], were labeled with
biotin. As shown in Figure 5A, we found significant
binding of nuclear protein to cyclin D1 (lane 2) while
LMP1 promoted more nuclear protein binding (lane 3),
indicating that LMP1 promoted STAT3 binding to the
cyclin D1 promoter. The complex in CNE1-LMP1 cells
was abolished by adding cold STAT3 binding sequence
(Figure 5A, lane 4) but not by a mutation in the STAT3
binding sequence (Figure 5A, lane 5) or a nonspecific
binding sequence (Figure 5A, lane 6). After we mutated
the plasmid containing functional mutated cyclin D1
promoters, we could not detect the band in either
CNE1 or CNE1-LMP1 cells (lanes 8 and 9 of Figure 5A).
After the CNE1 cells were treated with IL-6 to induce
STAT3 activation, we observed STAT3 binding in the
cyclin D1 promoter (Figure 5B). After the CNE1-LMP1
cells were treated with the STAT3 inhibitors WHI-P131
and PD98059 (Figure 5B), we observed that STAT3binding in the cyclin D1 promoter decreased. Taken
together, LMP1 promoted STAT3 binding to the Cyclin
D1 promoter.
To address whether nuclear EGFR is involved with the
cyclin D1 promoter directly, we mutated the cyclin D1
promoter sequence such that no transcription factor
binds. As shown in Figure 5C, biotin-labeled wild-type
EGFR oligonucleotide and nuclear EGFR formed a spe-
cific complex in CNE1- LMP1 cells (Figure 5C lane 3).
With a mutated EGFR probe, no specific complex band
was present (Figure 5C lane 5), whereas a weak band
was detected in CNE1 cells. Formation of this complex
from CNE1- LMP1 cells was blocked by competition
with the cold EGFR (Figure 5C lane 4) but not by
the mutated EGFR or nonspecific nucleotide NF-κB
(Figure 5C lanes 6 and 7). After blocking the EGFR
signaling pathway with the small molecule inhibitor
AG1478, the band indicating a complex was weaker in
the CNE1-LMP1 nuclear proteins (Figure 5D). To con-
firm that LMP1 controlled the cyclin D1 promoter, the
CNE1-LMP1 cells were treated with DZ1, which is a
Figure 4 Inhibitors and dominant negative mutants targeting the EGFR and STAT3 pathways attenuated LMP1-augmented cyclin D1
promoter activity. (A-B) Stable expression of EGFR-DN and STAT3β inhibited the LMP1-increased activity of cyclin D1. The indicated NPC cell
lines were transfected with a cyclin D1 promoter-reporter construct, a Renilla luciferase transfection control plasmid, and an EGFR-DN or STAT3-β
expression plasmid. Twenty-four hrs. after transfection, the cells were treated with DNAzymes or a control oligo (2 μM) for 12 hrs. Cells were
harvested at 36 hrs. after transfection and subjected to the luciferase assay. Firefly luciferase was measured and normalized to Renilla luciferase
activity. The results were expressed as fold induction of the reporter activity in vector-transfected CNE1 cells, which was assigned a value of 1.
(mean ± SD, n =3, *p < 0.05) (C) WHI-P131, PD98059 and AG1478 inhibited the activity of cyclin D1 induced by stable expression of LMP1.
CNE1-LMP1 cells were transfected with a cyclin D1 promoter-reporter construct and a Renilla luciferase plasmid as an internal control. Twenty-four
hrs. after transfection, the cells were treated with WHI-P131, PD98059, AG1478 or 0.1% DMSO for 2 hrs. The cells were harvested at 26 hrs. after
transfection and subjected to the luciferase assay. An empty firefly reporter vector served as a control (n = 3). * p < 0.05. (D) WHI-P131, PD98059 and
AG1478 inhibited the expression of cyclin D1 induced by stable expression of LMP1. The cells were harvested for Western Blot at 8 hrs. after the
treatment of WHI-P131, PD98059, AG1478 or 0.1% DMSO. β-actin was served as an internal control.
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http://www.jeccr.com/content/32/1/90specific LMP1-targeted DNAzyme construct [19]. Data
in Figure 5E showed that the complex band of biotin-
labeled EGFR nucleotide with nuclear protein weakened
in CNE1-LMP1 cells after treatment with DZ1. Taken
together, these results show that LMP1 regulates the
binding capacity of EGFR, STAT3 to the cyclin D1 pro-
moter region in vitro.
LMP1 induced EGFR and STAT3 to activate cyclin D1
gene expression
To address whether EGFR and STAT3 may be involved in
cyclin D1 activity, we knocked down EGFR or STAT3 with
siRNA. After we introduced EGFR siRNA or and STAT3
siRNA in CNE1-LMP1 cells (Figure 6A), the cyclin D1
promoter activity decreased compared to treatment with
nonspecific siRNA (siControl). We also used siRNA to
further confirm the roles of EGFR and STAT3 in theregulation of cyclin D1 mRNA. Knockdown of EGFR and
STAT3 with siRNA decreased the cyclin D1 mRNA level
in CNE1-LMP1 cells (Figure 6B). We could not detect a
stronger effect of the combined knockdown of EGFR and
STAT3 on cyclin D1 promoter activity or mRNA level. To
further confirm that both EGFR and STAT3 may be
involved in the cyclin D1 protein, we detected the cyclin
D1 protein level after we knocked down EGFR or STAT3
with siRNA. Data in Figure 6C showed that knockdown of
EGFR and STAT3 with siRNA decreased the cyclin D1
protein level in CNE1-LMP1 cells. To further address
how EGFR or STAT3 affects the cell cycle, we performed
FACS analysis on the CNE1-LMP1 cells after knockdown
of EGFR, STAT3 or both. Data in Figure 6D indicated that
the depletion of EGFR, STAT3 or both proteins altered
the cell cycle distribution especially at S phase with
the stimulation of LMP1. Taken together, these findings
Figure 5 LMP1 increased the binding ability of transcription factors EGFR and STAT3 to cyclin D1 promoter in vitro. (A) STAT3 binding
activities within the cyclin D1 promoter were examined by EMSA. A biotin-labeled wild-type STAT3 oligonucleotide probe was incubated with
nuclear extracts of CNE1 and CNE1-LMP1 cells in the presence of a 200-fold excess of unlabeled wild-type STAT3 (lane 4), unlabeled mutant STAT3
oligonucleotides (lane 5), or noncompetitive unlabeled NF-κB oligonucleotide (NS, lane 6). Biotin-labeled mutant STAT3 oligonucleotide probe
was incubated with nuclear extracts of the indicated NPC cell lines (lanes 8–9). (B) Ten micrograms of nuclear extracts were pre-incubated with
biotin-labeled STAT3 oligonucleotide probe in the presence of inhibitors directed against different phosphorylation sites of STAT3 (indicated
above each lane). (C) The biotin-labeled wild-type EGFR oligonucleotide probe was incubated with nuclear extracts of CNE1 and CNE1-LMP1 cells
in the presence of a 200-fold excess of unlabeled wild-type EGFR (lane 4), unlabeled mutant EGFR oligonucleotides (lane 6) or noncompetitive
unlabeled NFκB oligonucleotide (NS, lane 7), and then EGFR DNA binding activities were examined by EMSA. (D-E) The nuclear extracts of CNE1
and CNE1-LMP1 cells were pre-incubated with biotin-labeled EGFR oligonucleotide probe in the presence of inhibitors AG1478, directed against
phosphorylation of EGFR, or DNAzyme 1 (DZ1), targeting LMP1. RD: relative density.
Xu et al. Journal of Experimental & Clinical Cancer Research 2013, 32:90 Page 9 of 13
http://www.jeccr.com/content/32/1/90demonstrate that both EGFR and STAT3 are essential for
cyclin D1 expression in the presence of LMP1.
Discussion
cyclin D1 over-expression is important in the develop-
ment and progression of numerous cancers [48]. Regula-
tion of the cyclin D1 protein level is one of the critical
aspects in cell proliferation and tumor development
[49], indicating that cyclin D1 may be regarded as a
therapeutic target in cancer [50]. Cyclin D1 is upregu-
lated expression in NPC [51]. Overexpressed cyclin D1
in NPC increases the risk of tumor formation and local
disease recurrence [52]. Although cyclin D1 is known to
be a target gene of EGFR and STAT3 [46,53-56], its
transcriptional regulation remains elusive after the infec-
tion of virus. Our previous study reported that LMP1
encoded by EBV could regulate the nuclear accumula-
tion of EGFR and that nuclear EGFR could bind to the
promoters of cyclin D1 and cyclin E to accelerate theG1/S phase transition. Another report showed that EBV
LMP1 signals through the Janus kinase 3 (JAK3) and
ERK1/2 pathways upon the activation of STAT3 and
STAT transactivation to induce expression of VEGF
[34]. Overexpressed EGFR could activate specifically and
persistently STAT3 after the decrease TGF-beta signaling
pathway [57]. The key contribution of the present study
is to provide a link between signaling via LMP1/EGFR
and LMP1/STAT3, which is consistent with the previous
findings that EBV LMP1 could promote the expression
of EGFR [58,59].
The mechanism by which EBV LMP1 induces EGFR
and STAT3 to enhance the promoter activity and ex-
pression of cyclin D1 involves physical and functional
interaction between EGFR and STAT3. This observation
is in agreement with other reports that nuclear EGFR
interacts with transcription factors, such as STAT3,
E2F1, STAT5 and TIF2 to induce the expression of some
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Figure 6 Cyclin D1 expression is reduced in CNE1-LMP1 cells after treatment with EGFR siRNA and STAT3 siRNA. (A) Dual luciferase-reporter
assays were performed in CNE1-LMP1 cells after co-transfection with either control siRNA (siControl), EGFR siRNA (siEGFR), or STAT3 siRNA
(siSTAT3) in addition to cyclin D1 promoter-reporter constructs and a Renilla luciferase transfection control plasmid. Firefly luciferase was
measured and normalized to Renilla luciferase activity. The fold change in cyclin D1 expression by the indicated siRNA is displayed in each case.
The control siRNA served as a non-targeting control. (mean ± SD, n =3, *p < 0.05) (B) The cells were incubated with medium containing the
indicated siRNAs for 72 h. Total RNA was isolated from the cells and subjected to real-time PCR, using specific primers designed to amplify
cyclin D1. β-actin mRNA served as an internal control. (mean ± SD, n =3, *p < 0.05, **p < 0.01). (C) Western Blot was performed in CNE1-LMP1
cells after co-transfection with the indicated siRNAs for 72 h. β-actin was served as an internal control. (D) FACS was performed in CNE1 and
CNE1-LMP1 cells after co-transfection with the indicated siRNAs for 72 h. The data are presented from three independent experiments.
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B-Myb, Aurora A and COX-2, have been reported, yet
these studies did not support cyclin D1 as the target
gene co-regulated by EGFR and other transcription fac-
tors after the infection of EBV, such as in the work of
EGFR and STAT3 co-affecting on iNOS and STAT1 in
breast cancer [31,57]. Together, these findings suggest
the EGFR-STAT3 axis signaling pathway is critical in
regulating cellular transcriptional and biologic properties
in different carcinomas in response to diverse carcino-
gens such as virus infection.
Our previous studies reported EBV LMP1 induces in
both expression and phosphorylation of EGFR in a dose-
dependent manner [21,45], and other authors demon-
strated EGFR that accumulated in the nucleus of breast
carcinoma cell lines and esophageal cancer tissues was
highly tyrosine-phosphorylated [54,65]. Meanwhile, we
found EBV LMP1 expressing cells exhibited more nuclear
accumulation of Tyr 705-phophorylated STAT3 (pY-
STAT3) [35,45]. EGFR physically interacts and functionallycooperates with STAT3 at both the cytoplasmic and nu-
clear levels. As reported, EGFR and phosphorylated STAT3
were strongly expressed in the nucleus of cancer cells in
surgical and biopsy specimens of nasopharyngeal tissues
from NPC patients in southern China [35,66], suggesting
that EGFR- and STAT3-dependent mechanisms are im-
portant for carcinogenesis.
It has been shown that LMP1 induces cyclin D1 ex-
pression through EGFR in NPC cells [23]. The present
study show that the promoter activity and mRNA ex-
pression level of cyclin D1 in LMP1-expressing cells
could be decreased by co-transfecting the plasmids of
mutated EGFR/STAT3 or siRNA for EGFR and
siSTAT3. However, we did not find the cooperative ef-
fect of siEGFR and siSTAT3 at both mRNA and protein
levels of cyclin D1. We provide the evidence showing
cyclin D1 might be modulated by STAT3 induced by
EBV LMP1, illustrating the importance of the JAK/
STAT signaling pathway on EBV LMP1 induced cyclin
D1 transcription and expression.
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radiotherapy for early stage disease and concurrent
chemoradiotherapy for advanced disease [67,68].
EGFR and STAT3 are good targets for cancers treat-
ment. Thus, agents such as the anti-EGFR antibody
cetuximab, the EGFR tyrosine kinase inhibitor gefitinib,
and STAT3 inhibitors (such as S3I-201 or JSI-124) could
be used in preclinical models or each phase of clinical
trials [69-71]. Interestingly, a novel STAT3 inhibitor S3I-
1747 selectively interrupt the interaction of EGFR and
STAT3 directly [72]. Those reports also suggested that
either an anti-EGFR or anti-STAT3 agent might be a po-
tent chemopreventive agent for patients with anti-invasion
and anoikis-sensitizing activities. Therapies such as
monoclonal antibodies and tyrosine kinase inhibitors
targeting EGFR have demonstrated limited anti-tumor
efficacy [71,73]; however, reports of combined target-
ing of EGFR and STAT3 are few. Recently, EBV
LMP1-specific DNAzyme, DZ1, inhibits the majority
of oncogenic signaling pathways converging on sets of
transcription factors that ultimately control gene ex-
pression patterns resulting in tumor formation, pro-
gression, and metastasis. [19] Our data showed that
DZ1 can inhibit EBV LMP1-induced promoter activity
of cyclin D1 via EGFR or STAT3 and that DZ1
enhanced cyclin D1 promoter inhibition based on ex-
periments with mutants of EGFR or STAT3. These
results suggest that combining inhibitors for EGFR/
STAT3 and DZ1 in LMP-expressing cancers may be a
promising therapeutic strategy. The combination of
Src and EGFR inhibition with Gemcitabine treatment
in STAT3-mediated therapy-resistant pancreatic tu-
mors was also effective at inhibiting the growth of
xenografts of both therapy-sensitive and -resistant
pancreatic cancer cells in vivo without increasing tox-
icity [73]. It is possible that EGFR and STAT3, indi-
vidually or as a pair, contribute to tumor progression.
Alternatively, crosstalk between signaling pathways
provides a potential route to overcome the blockade
of a single or double targeted therapies, but this can
be overcome by the blockade of multiple targets. Our
data provide further evidence that the combination of
three inhibitors may be efficacious for cancer, and
more extensive investigation will be required.
In summary, we found that EBV LMP1 enhances
the transcriptional activity and mRNA level of the
cyclin D1 gene in CNE1 cells. This underlying mech-
anism for cyclin D1 regulation involves regulated
binding of EGFR and STAT3 in the cyclin D1 pro-
moter region as well as increasing the promoter activ-
ity of the cyclin D1 gene. Such a mechanism may
partially contribute to the proliferation and growth of
tumor cells with an LMP1-induced increase in the
nuclear accumulation of EGFR and STAT3.Additional file
Additional file 1: Figure S1. LMP1 promoted the interaction of
phosphorylated EGFR and phosphorylated STAT3. Two mg of protein
from cell lysates were immunoprecipitated with an anti-phosphorylated
EGFR antibody (p-EGFR) and analyzed by Western blotting with a phos-
phorylated STAT3 (p-STAT3) and p-EGFR antibodies. Negative
controls included immunoprecipitation with an unrelated antibody (IgG).
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